Abstract:Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly mediated by persistent intrahepatic immunopathology. With the characterization of unique anatomical and immunological structure, the liver is also deemed an immunological organ, which gives rise to massive cytokines and chemokines under pathogenesis conditions, having significant implications for the progression of HBV infection. The intrahepatic innate immune system is responsible for the formidable source of cytokines and chemokines, with the latter also derived from hepatic parenchymal cells. In addition, systemic cytokines and chemokines are disturbed along with the disease course. Since HBV is a stealth virus, persistent exposure to HBV-related antigens confers to immune exhaustion, whereby regulatory cells are recruited by intrahepatic chemokines and cytokines, including interleukin-10 and transforming growth factor β, are involved in such series of causal events. Although the considerable value of two types of available approved treatment, interferons and nucleos(t)ide analogues, effectively suppress HBV replication, neither of them is sufficient for optimal restoration of the immunological attrition state to win the battle of the functional or virological cure of CHB infection. Notably, cytokines and chemokines play a crucial role in regulating the immune response. They exert effects by directly acting on HBV or indirectly manipulating target immune cells. As such, specific cytokines and chemokines, with a potential possibility to serve as novel immunological interventions, combined with those that target the virus itself, seem to be promising prospects in curative CHB infection. Here, we systematically review the recent literature that elucidates cytokine and chemokine-mediated pathogenesis and immune exhaustion of HBV infection and their dynamics triggered by current mainstream anti-HBV therapy. The predictive value of disease progression or control and the immunotherapies target of specific major cytokines and chemokines in CHB infection will also be delineated.

[Advances in Liver Immunology in 2018].

Cellular Immune Response In Patients With Chronic Hepatitis B Virus Infection

Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B: A balance between immunity strength and liver injury extent.

Increasing LAG-3 Expression Suppresses T-cell Function in Chronic Hepatitis B

Immune Response of TLRs Mediated Anti-Hepatitis B Virus

Cytokines and Chemokines in HBV Infection

[Research Advances in Diagnosis and Treatment of Liver Failure in 2016].

Interorgan communication with the liver: novel mechanisms and therapeutic targets

IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases.

Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer

Liver in Infections: a Single-Cell and Spatial Transcriptomics Perspective

Immune suppression in chronic hepatitis B infection associated liver disease: A review

Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection

Increased serum levels of advanced glycation end-products and diabetic complications.

Interplay Between Hepatitis B Virus and the Innate Immune Responses:Implications for New Therapeutic Strategies

Focus on Dysregulated Adaptive Immunity in Chronic Hepatitis B: A Promising Direction for Immunotherapy

Adaptive response in hepatitis B virus infection

NK Cells in Liver Homeostasis and Viral Hepatitis

Activation and Function of Hepatic Nk Cells in Hepatitis B Infection: an Underinvestigated Innate Immune Response

Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications

Immune modulation of gut microbiota and its metabolites in chronic hepatitis B